Is visual field constriction in epilepsy patients treated with vigabatrin reversible?

Area of Science:

• Ophthalmology
• Neurology
• Pharmacology

Background:

• Vigabatrin (VGB) is an antiepileptic drug associated with visual field constriction (VFC) in up to 40% of patients.
• The reversibility of VGB-associated VFC remains controversial, with some evidence suggesting it does not resolve within months of drug cessation.
• Limited long-term studies exist on the persistence of VGB-associated VFC.

Purpose of the Study:

• To investigate the long-term reversibility of visual field constriction (VFC) in epilepsy patients treated with vigabatrin (VGB).
• To assess changes in visual field size after discontinuing or reducing VGB dosage.

Main Methods:

• A follow-up study involving 15 epilepsy patients with VGB-associated VFC and normal ophthalmological exams.
• Kinetic and static perimetry were conducted at baseline, one year, and two years post-VFC diagnosis.
• Visual field size was compared across time points, analyzing outcomes for patients who stopped VGB, reduced dosage, or continued treatment.

Main Results:

• No statistically significant difference in visual field size was observed between baseline and one or two-year follow-up examinations.
• This lack of change was consistent in patients who discontinued VGB (n=11) and those who continued on a reduced dosage (n=4).

Conclusions:

• Vigabatrin-associated visual field constriction (VFC) appears to be irreversible in epilepsy patients, even after drug cessation.
• The findings suggest that VFC resulting from VGB treatment may be a permanent condition.
• Further long-term studies are warranted, but current evidence indicates a lack of reversibility.